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Ivacaftor, a CFTR potentiator that enhances chloride transport by acting directly on CFTR to increase its channel gating activity, has been
evaluated in patients with different CFTR mutations. Several previous analyses have reported no statistical correlation between change from
baseline in ppFEV1 and reduction in sweat chloride levels for individuals treated with ivacaftor. The objective of the post hoc analysis described
here was to expand upon previous analyses and evaluate the correlation between sweat chloride levels and absolute ppFEV1 changes across
multiple cohorts of patients with different CF-causing mutations who were treated with ivacaftor. The goal of the analysis was to help deﬁne the
potential value of sweat chloride as a pharmacodynamic biomarker for use in CFTR modulator trials. For any given study, reductions in sweat
chloride levels and improvements in absolute ppFEV1 were not correlated for individual patients. However, when the data from all studies were
combined, a statistically signiﬁcant correlation between sweat chloride levels and ppFEV1 changes was observed (p b 0.0001). Thus, sweat
chloride level changes in response to potentiation of the CFTR protein by ivacaftor appear to be a predictive pharmacodynamic biomarker of lung
function changes on a population basis but are unsuitable for the prediction of treatment beneﬁts for individuals.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Cystic ﬁbrosis; Ivacaftor; Sweat chloride; FEV1Cystic fibrosis (CF) is an autosomal recessive hereditary
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,pean CCFTR-mediated ion transport in CF results in a wide range of
symptoms, including abnormal electrolyte concentrations in the
sweat of patients with CF [3].
Ivacaftor, a CFTR potentiator that enhances chloride transport
by acting directly on CFTR to increase its channel gating activity,
has been evaluated in patients with different CFTR mutations
[4–8]. In a Phase 2 study of patients carrying the G551D
mutation on at least one allele, administration of ivacaftor
resulted in an early and substantial mean decrease in sweat
chloride levels, as well as early improvements in lung function as
measured by percent predicted forced expiratory volume in 1 s
(ppFEV1) [9,10]. A dose-dependent effect was seen on sweat
chloride levels with ivacaftor treatment (25 mg to 250 mg) in this
trial [10], suggesting that sweat chloride may also correlate with
ppFEV1. Seliger et al. conducted a post hoc analysis of two
double-blind, multicenter studies to investigate the value of sweatystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
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function in individuals with CF carrying at least one copy of
the G551D–CFTR mutation treated with ivacaftor [4,5,11]. The
analysis showed no statistical correlation between change from
baseline in ppFEV1 and reduction in sweat chloride levels for
individuals [11], thus confirming data previously published by
Durmowitz et al. [12]. The efficacy of ivacaftor has also been
evaluated in patients harboring numerous other mutations [7,8]
who were predicted to respond to ivacaftor therapy based on in
vitro data [13] and in patients homozygous for the F508del
mutation [6] who were not expected to show a clinically
meaningful response based on in vitro response data [13].
The objective of the post hoc analysis described here was
to expand upon previous analyses and evaluate the correlation
between sweat chloride levels and absolute ppFEV1 changes
across multiple cohorts of patients with different CF-causing
mutations who were treated with ivacaftor. The goal of the
analysis was to help define the potential value of sweat chloride
as a pharmacodynamic biomarker for use in CFTR modulator
trials. Eight Phase 2 and 3 clinical studies contributed data to
this analysis of the relationship between sweat chloride levels
and ppFEV1 among patients with CF treated for at least 14 days
with ivacaftor monotherapy. Trial information and treatment
details for the eight studies are shown in Table 1.
For any given study, reductions in sweat chloride levels
and improvements in absolute ppFEV1 were not correlated for
individual patients [6]. However, when the data from all studies
were combined, a statistically significant correlation between
sweat chloride levels and ppFEV1 changes was observed
(p b 0.0001). In Fig. 1, each data point corresponds to a par-
ticular study and dose and marks the mean absolute change
from baseline (and 95% confidence interval [CI]). Only patients
with complete data, i.e, who had baseline and end-of-treatment
values for ppFEV1 and sweat chloride were included in the
analyses. For study 110 (R117H) [7] patients aged b18 years
were excluded since baseline FEV1 values were considered
normal; the remaining patients were stratified according to theirTable 1
Study-level features of the post hoc analysis describing the correlation between swea
ivacaftor in clinical studies.
Trial identification number Age (y) N a Mutation
VX770-101 [10] ≥18 42 G551D
VX770-102 [4] ≥12 78 G551D
VX770-103 [5] 6–11 23 G551D
VX770-104 [6] ≥12 107 F508del homozyg
VX770-106 [14] ≥6 17 G551D
VX770-110 [7] ≥6
Patients aged b18 years were
excluded from analysis c
18 R117H
VX770-111 [8] ≥6 32 All non-G551D gat
VX770-113 [14] ≥12 21 Clinical evidence o
CF, cystic fibrosis; ppFEV1, percent predicted forced expiratory volume in 1 s; q12
a Of the 353 patients identiﬁed, 338 patients had baseline and end-of-treatment v
patients with G970R were excluded, as were patients with R117H who did not have
b Eligible patients had the opportunity to participate in an open-label extension st
c Remaining patients were stratiﬁed according to conﬁrmed 5T/7T status. One ou
who discontinued after week 8 was excluded.confirmed 5T/7T status and plotted separately in the graph.
Patients in study 111 had a mixed group of non-G551D gating
CFTR mutations [8]. Responses in patients with the G970R
mutation, excluded from the analyses, were not consistent with
those seen in the other gating mutations and research into this
mutation type is ongoing.
Each data point corresponds to a particular study and shows
the mean absolute change (and its 95% CI) from baseline in
percentage points for FEV1. In all studies, patients were treated
with ivacaftor 150 mg q12h, except for study 101 in which
patients were treated with one of four doses of ivacaftor (25, 75,
150, or 250 mg) q12h plotted individually. Relative sample
size is indicated by symbol size in the figure. Solid line shows
the fit of the weighted linear model (weighted by number of
patients in each study); r2 = 0.889, p b 0.0001, slope = −0.168
[95% CI: −0.21, −0.13], intercept =0.95 [95% CI: −0.56, 2.51].
Dashed lines show the 95% CI of the fit.
CF, cystic fibrosis; CI, confidence interval; ppFEV1, percent
predicted forced expiratory volume in 1 s; q12h, every 12 h.
Fig. 2 depicts the absolute changes from baseline in ppFEV1
and sweat chloride levels for each individual patient enrolled in
the eight clinical trials analyzed. The statistically significant
correlation between sweat chloride levels and ppFEV1 changes
observed for mean values across the full dataset of studies was
also observed for individual changes (p b 0.0001, for both).
Each data point corresponds to an individual study par-
ticipant and shows the absolute change from baseline in
percentage points for FEV1 plotted against absolute change
in sweat chloride. Straight lines show fit obtained by linear
regression. Contours correspond to levels of data density and
show consistent correlation and reinforce the observed trend
line. The red line represents the LOESS regression. In all
studies, patients were treated with ivacaftor 150 mg q12h,
except for study 101 in which patients were treated with four
doses of ivacaftor (25, 75, 150, or 250 mg) q12h. Pearson
correlation: −0.339 [95% CI: −0.429, −0.241]; linear fit:
slope = −0.115, intercept =2.48, p b 0.0001.t chloride levels and absolute ppFEV1 changes in patients with CF who received
Treatment regimen
Part A: ivacaftor 25, 50, 75, or 150 mg q12h for 14 d
Part B: ivacaftor 150 or 250 mg q12h for 28 d
Ivacaftor 150 mg q12h for 48 wks
Ivacaftor 150 mg q12h for 48 wks
ous Ivacaftor 150 mg q12h for 16 wks b
Ivacaftor 150 mg q12h for 28 days
Ivacaftor 150 mg q12h for 24 wks b
ing mutations exceptG970R Ivacaftor 150 mg q12h for 8 wks b
f CFTR residual function Ivacaftor 150 mg q12h
h, every 12 h.
alues for ppFEV1 and sweat chloride and were included in the analyses. Four
conﬁrmed 5T or 7T status.
udy.
tlying patient with an immediate and continuing decrease of N20% in ppFEV1
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Fig. 1. Correlation between absolute change from baseline of ppFEV1 and sweat
chloride level (mmol/L) in patients with CF treated with ivacaftor.
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predicted forced expiratory volume in 1 s; q12h, every 12 h.
A combined analysis of data from eight clinical trials
evaluating ivacaftor monotherapy in patients with CF showed
that, over a wide range of sweat chloride responses to treatment, a
statistically significant association can be detected with absolute
percentage point changes in ppFEV1. This correlation may be
useful for predictingmean treatment effects in clinical trials based
on mean sweat chloride changes. However, more experimental
and real-world data would be required to provide guidance on the
utility of sweat chloride changes for clinical practice.
Sweat chloride level changes do not appear to predict
improvements in ppFEV1 for an individual, presumably due-100
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Fig. 2. Correlation between individual absolute change from baseline of ppFEV1
and sweat chloride level (mmol/L) in patients with CF treated with ivacaftor.to the multiplicity of factors affecting lung function, including
(but not limited to) irreversible lung tissue damage, pulmonary
exacerbation rates, and long-term treatment adherence. Unlike
the lung, CFTR dysfunction in the sweat gland does not lead to
tissue damage, and sweat chloride levels remain relatively
constant, with small increases possible from birth through age
12, followed by decreases thereafter [15]. A recent analysis of
twins/siblings with CF concluded that while CFTR mutation
was the predominant contributor to variability in sweat chloride,
environmental factors and test variability contributed up to 23%
of the variability observed [16]. Furthermore, sweat chloride level
changes are very sensitive to short-term treatment adherence, and
missed doses prior to testing have been shown to affect testing
results [17].
In conclusion, sweat chloride level changes in response
to potentiation of the CFTR protein by ivacaftor appear to be a
predictive pharmacodynamic biomarker of lung function changes
on a population basis but are unsuitable for the prediction of
treatment benefits for individuals.
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